Lu-177 PSMA I&T Therapy for Prostate Cancer; Treatment Response, Treatment Toxicity, and Survival Results

---

Acar E., Sonmezer B., DEREBEK E., BEKİŞ R., ÖZDOĞAN Ö., Kaya G. C.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, cilt.3, sa.3, ss.158-164, 2019 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 3 Sayı: 3
• Basım Tarihi: 2019
• Doi Numarası: 10.30621/jbachs.2019.708
• Dergi Adı: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.158-164
• Anahtar Kelimeler: PSMA, prostate cancer, radioligand therapy, mCRPC, theranostic, precision medicine
• Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: This study aims to evaluate the serum PSA response, Ga-68 PSMA PET/CT response, hematological/nephrological toxicity and survival results of patients with castration-resistant metastatic prostate cancer who are receiving Lu-177 PSMA therapy.